Researchers had thought complement could be used to fight cancers as part of an antibody-based vaccine, as antibody binding is one of the factors that can set off a complement cascade. However, some ...

InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderma Gangraenosum in a phase 3 trial. The company has ...